deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT02460991

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma (SOLACE)

A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization With Drug Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally Advanced Hepatocellular Carcinoma

Sponsor: Boston Scientific Corporation

Conditions Hepatocellular Carcinoma Hepatoma Liver Cell Carcinoma
Interventions DEB-TACE Sorafenib
Updated 11 times since 2017 Last updated: Jan 25, 2021 Started: Nov 30, 2015 Primary completion: Jun 5, 2017 Completion: Jun 5, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow enrollment

Other terminated trials from Boston Scientific Corporation

More terminations from Boston Scientific Corporation

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

A PHASE3 clinical study on Hepatocellular Carcinoma and Hepatoma, this trial is terminated or withdrawn. The trial is conducted by Boston Scientific Corporation and has accumulated 11 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotActive Not Recruiting~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshotTerminated~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotTerminated~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotTerminated~Dec 2018 – ~Jan 2021 · 25 months · monthly snapshotTerminated~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotTerminated~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Mar 2021 — Dec 2021 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Mar 2021 [monthly]

    Terminated PHASE3

▶ Show 6 earlier versions

  1. Dec 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  2. Jun 2018 — Dec 2018 [monthly]

    Terminated PHASE3

  3. Dec 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    Phase: NA → PHASE3

  4. Jul 2017 — Dec 2017 [monthly]

    Terminated NA

    Status: Active Not Recruiting → Terminated

  5. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting NA

    Status: Recruiting → Active Not Recruiting

  6. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boston Scientific Corporation
Data source: Boston Scientific Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations